Daniel Kohlstaedt, managing director and founder of PurpleLeaf Strategy, outlines the key elements brand planning platform technology must have to help brand teams optimise their strategies.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh